Search

FLORAL

Long-term treatment with etavopivat in people with sickle cell disorder or thalassaemia Click here

NIHR Rapid Service Evaluation Team (REVAL)

Evaluation of pilot hyperacute units to deliver acute sickle cell care as part of a wider programme of quality improvement (SCD)In response to recognition of avoidable deaths and failures of […]

HIBISCUS

Exploring the use of a new drug in patients with sickle cell disease. The HIBISCUS study started at the King’s College Hospital Denmark Hill campus in June 2022 with patients […]

Haematology Lived Experience and Outcomes (HALO)

HALO is a research study looking at the survival rates of people diagnosed with Sickle Cell Disorder or Beta Thalassemia, acute Lymphoblastic or acute Myeloid Leukaemia in childhood and the long-term effects of that diagnosis and treatment.